# Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma

> **NCT04367948** · NA · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 200 (estimated)

## Conditions studied

- Tumor, Solid
- Positron-Emission Tomography
- Lymphoma

## Interventions

- **DIAGNOSTIC_TEST:** 18F-FDG and 68Ga-NOTA-FAPI04 PET/CT
- **DIAGNOSTIC_TEST:** 18F-FDG and 18F-NOTA-FAPI04 PET/CT

## Key facts

- **NCT ID:** NCT04367948
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04367948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04367948, "Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04367948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*